免疫检查点抑制剂联合治疗IV期胰腺癌1例并文献复习
Immune Checkpoint Inhibitor Combination Therapy for Stage IV Pancreatic Cancer in 1 Case and Literature Review
摘要: 胰腺癌是一种较为常见的消化系统肿瘤,其恶性程度极高、患者总体预后不良。由于胰腺癌发病隐匿,缺乏有效的早期诊断方法。针对中晚期胰腺癌,目前尚缺乏有效的治疗方案。想要改善胰腺癌的治疗现状,不能仅靠手术治疗,化疗、免疫治疗及靶向治疗同样重要。近年来,免疫治疗在多种恶性肿瘤的治疗中取得重大进展,在胰腺癌的治疗中也有所突破。因此我们在此报道了一例胰腺癌术后复发转移患者应用免疫检查点抑制剂联合治疗的病例,并对胰腺癌的治疗进展进行综述。
Abstract: Pancreatic cancer is a relatively common tumor of the digestive system, which has a high degree of malignancy and poor overall prognosis. Due to the insidious onset of pancreatic cancer, there is a lack of effective early diagnosis methods. For intermediate and advanced pancreatic cancer, there is currently a lack of effective treatment options. To improve the treatment status of pancreatic cancer, surgery alone cannot be relied upon, and chemotherapy, immunotherapy and targeted therapy are equally important. In recent years, immunotherapy has made significant progress in the treatment of a variety of malignant tumors, and there have been breakthroughs in the treatment of pancreatic cancer. Therefore, we report here a case of immune checkpoint inhibitor combination therapy in patients with recurrent and metastatic pancreatic cancer after surgery, and review the treatment progress of pancreatic cancer.
文章引用:韩娜, 孙帆, 张晓春. 免疫检查点抑制剂联合治疗IV期胰腺癌1例并文献复习[J]. 临床医学进展, 2022, 12(11): 10299-10303. https://doi.org/10.12677/ACM.2022.12111485

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
[3] Khorana, A.A., Mangu, P.B., Berlin, J., et al. (2016) Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 34, 2541-2556. [Google Scholar] [CrossRef
[4] Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., et al. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33. [Google Scholar] [CrossRef] [PubMed]
[5] Wei, S.C., Duffy, C.R. and Allison, J.P. (2018) Fun-damental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. [Google Scholar] [CrossRef
[6] Kasakovski, D., Skrygan, M., Gambichler, T., et al. (2021) Advances in Targeting Cutaneous Melanoma. Cancers (Basel), 13, 2090. [Google Scholar] [CrossRef] [PubMed]
[7] Majidpoor, J. and Mortezaee, K. (2021) The Efficacy of PD-1/PD-L1 Blockade in Cold Cancers and Future Perspectives. Clinical Immunology, 226, Article ID: 108707. [Google Scholar] [CrossRef] [PubMed]
[8] Patnaik, A., Kang, S.P., Rasco, D., et al. (2015) Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 21, 4286-4293. [Google Scholar] [CrossRef
[9] Weiss, G.J., Blaydorn, L., Beck, J., et al. (2018) Phase Ib/II Study of Gemcitabine, Nab-Paclitaxel, and Pembrolizumab in Metastatic Pancreatic Adenocarcinoma. Investigational New Drugs, 36, 96-102. [Google Scholar] [CrossRef] [PubMed]
[10] Cancer Genome Atlas, N. (2012) Comprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature, 487, 330-337. [Google Scholar] [CrossRef] [PubMed]
[11] Hu, Z.I., Shia, J., Stadler, Z.K., et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 24, 1326-1336. [Google Scholar] [CrossRef